KR20200109293A - 자간전증 바이오마커 및 관련된 시스템 및 방법 - Google Patents

자간전증 바이오마커 및 관련된 시스템 및 방법 Download PDF

Info

Publication number
KR20200109293A
KR20200109293A KR1020207009958A KR20207009958A KR20200109293A KR 20200109293 A KR20200109293 A KR 20200109293A KR 1020207009958 A KR1020207009958 A KR 1020207009958A KR 20207009958 A KR20207009958 A KR 20207009958A KR 20200109293 A KR20200109293 A KR 20200109293A
Authority
KR
South Korea
Prior art keywords
preeclampsia
proteins
clec4a
kim1
probes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207009958A
Other languages
English (en)
Korean (ko)
Inventor
매튜 쿠퍼
샤라 싱
카렌 에이 에프 코프랜드
린달 허스터버그
아민 알 마즈룸
모함매드 아바시
마스트로 리차드 길리오 델
Original Assignee
프로제너티, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로제너티, 인크. filed Critical 프로제너티, 인크.
Publication of KR20200109293A publication Critical patent/KR20200109293A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
KR1020207009958A 2017-09-13 2018-09-13 자간전증 바이오마커 및 관련된 시스템 및 방법 Ceased KR20200109293A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558184P 2017-09-13 2017-09-13
US62/558,184 2017-09-13
PCT/US2018/050893 WO2019055661A1 (en) 2017-09-13 2018-09-13 PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS

Publications (1)

Publication Number Publication Date
KR20200109293A true KR20200109293A (ko) 2020-09-22

Family

ID=65723874

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207009958A Ceased KR20200109293A (ko) 2017-09-13 2018-09-13 자간전증 바이오마커 및 관련된 시스템 및 방법

Country Status (10)

Country Link
US (3) US20200264188A1 (https=)
EP (1) EP3682250A4 (https=)
JP (1) JP2020533595A (https=)
KR (1) KR20200109293A (https=)
CN (1) CN111094988A (https=)
AU (1) AU2018331400A1 (https=)
CA (1) CA3075688A1 (https=)
MX (1) MX2020002788A (https=)
SG (1) SG11202002065VA (https=)
WO (1) WO2019055661A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS
GB202012830D0 (en) * 2020-08-17 2020-09-30 Univ Tartu Method of prognosing preeclampsia
US20240241138A1 (en) * 2021-05-07 2024-07-18 University Of North Texas Health Science Center At Fort Worth Blood Test to Screen Out Parkinson's Disease
CN113724873B (zh) * 2021-08-31 2024-01-12 陕西佰美基因股份有限公司 一种基于mlp多平台校准的子痫前期风险预测方法
AU2022201995A1 (en) * 2022-01-27 2023-08-10 Speclipse, Inc. Liquid refining apparatus and diagnosis system including the same
CN114878837A (zh) * 2022-05-31 2022-08-09 国家卫生健康委科学技术研究所 与妊娠期高血压疾病诊断相关的血清预测标志物
CN117012276A (zh) * 2023-06-30 2023-11-07 佛山市妇幼保健院 子痫前期溶酶体相关生物标志物的筛选方法及其应用
CN119206371B (zh) * 2024-11-22 2025-05-13 南京红十字血液中心 一种基于机器学习的血型辅助研判方法

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777964A (en) 1986-01-02 1988-10-18 David Briggs System for obtaining blood samples and submitting for testing of aids
US5096830A (en) 1987-11-17 1992-03-17 Adeza Biomedical Corporation Preterm labor and membrane rupture test
US5223440A (en) 1987-11-17 1993-06-29 Adeza Biomedical Corporation Ex vivo product of conception test to determine abortion
US4919889A (en) 1988-09-15 1990-04-24 Aspen Diagnostics Corporation Sample collection and transport fluid composition
US5281522A (en) 1988-09-15 1994-01-25 Adeza Biomedical Corporation Reagents and kits for determination of fetal fibronectin in a vaginal sample
WO1993009438A1 (en) 1991-11-04 1993-05-13 Adeza Biomedical Corporation Screening method for identifying women at increased risk for preterm delivery
WO1993009432A1 (en) 1991-11-04 1993-05-13 Adeza Biomedical Corporation Screening method for identifying women at increased risk for imminent delivery
US5516702A (en) 1991-11-06 1996-05-14 Adeza Biomedical Corporation Screening method for identifying women at increased risk for imminent delivery
WO1994019693A1 (en) 1993-02-24 1994-09-01 Baxter Diagnostics Inc. Immobilization of specific binding assay reagents
US5898005A (en) 1993-02-24 1999-04-27 Dade Behring Inc. Rapid detection of analytes with receptors immobilized on soluble submicron particles
ATE226959T1 (de) 1993-03-23 2002-11-15 Victor Voroteliak Methode zur detektion von rissen in amniomembranen bei schwangeren säugetieren
US5431171A (en) 1993-06-25 1995-07-11 The Regents Of The University Of California Monitoring fetal characteristics by radiotelemetric transmission
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
US5650394A (en) 1993-11-04 1997-07-22 Adeza Biomedical Use of urinastatin-like compounds to prevent premature delivery
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5641636A (en) 1994-05-20 1997-06-24 University Of Pennsylvania Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity
US6140099A (en) 1994-05-20 2000-10-31 The Trustees Of The University Of Pennsylvania Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity
CA2211204C (en) 1995-01-26 2003-10-07 Merck Frosst Canada Inc. Prostaglandin receptor dp
KR19990067153A (ko) 1995-10-31 1999-08-16 사지게이쪼 프로스타글란딘 디 신타아제에 특이적인 단일클론항체
US6678669B2 (en) 1996-02-09 2004-01-13 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
US6120460A (en) 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6544193B2 (en) 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
FI963989A7 (fi) 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
US6376199B1 (en) 1997-03-07 2002-04-23 The Hospital For Sick Children (Hsc) Methods to diagnose a required regulation of trophoblast invasion
US6610480B1 (en) 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
US6875567B1 (en) 1997-11-10 2005-04-05 Genentech, Inc. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6506789B2 (en) 1998-06-03 2003-01-14 Shionogi & Co., Ltd. Methods for the treatment of itching comprising administering PGD2 receptor antagonist
US6149590A (en) 1998-07-22 2000-11-21 Smith; Ramada S. System for identifying premature rupture of membrane during pregnancy
US20010025140A1 (en) 1998-07-22 2001-09-27 Torok Brian A. System for identifying premature rupture of membrane during pregnancy
US6126597A (en) 1998-07-22 2000-10-03 Smith; Ramada S. System for identifying premature rupture of membrane during pregnancy
US7109044B1 (en) 1998-09-04 2006-09-19 Maruha Corporation Method of detection and disease state management for renal diseases
JP2002528500A (ja) 1998-10-29 2002-09-03 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム チアゾリジンジオン誘導体の早期分娩または授乳期間における子宮収縮を予防するための使用
JP2000249709A (ja) 1999-02-26 2000-09-14 Maruha Corp 冠血管インターベンション施行後の再狭窄の予測方法
US6126616A (en) 1999-06-21 2000-10-03 Sanyal; Mrinal K. Collection of biological products from human accessory reproductive organs by absorbent systems
JP3486408B2 (ja) 1999-08-23 2004-01-13 株式会社ビー・エム・エル 物質のヒトプロスタグランジンｄ２受容体に対する性質の同定方法
FR2809182B1 (fr) 2000-05-18 2003-08-15 Univ Rene Descartes Detection de l'il-6 pour la prevision des risques d'accouchement premature
US20010053876A1 (en) 2000-06-15 2001-12-20 Torok Brian A. System for identifying premature rupture of membrane during pregnancy
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
JP3752219B2 (ja) 2000-07-21 2006-03-08 マルハ株式会社 痴呆性疾患の鑑別方法
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
US20020046054A1 (en) 2000-08-28 2002-04-18 Morand Patrick G. Use of blood and plasma donor samples and data in the drug discovery process
US7217725B2 (en) 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
EP1351985A2 (en) 2000-10-16 2003-10-15 Bayer Aktiengesellschaft Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
US7635571B2 (en) 2000-12-07 2009-12-22 Siemens Healthcare Diagnostics Products Gmbh Amplified signal in binding assays
JP4279561B2 (ja) 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
WO2003008978A2 (en) 2001-07-18 2003-01-30 Merck Frosst Canada & Co. Eosinophil prostaglandin d2 receptor assays
US20040197834A1 (en) 2001-07-20 2004-10-07 Francois Gervais Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
US20050101841A9 (en) 2001-12-04 2005-05-12 Kimberly-Clark Worldwide, Inc. Healthcare networks with biosensors
AU2003247667A1 (en) 2002-07-01 2004-01-19 University Of Rochester Medical Center Method for determination of likelihood of occurrence of preterm labor in pregnant females
ES2534926T3 (es) 2002-07-19 2015-04-30 Beth Israel Deaconess Medical Center Métodos para tratar la preeclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
EP2204654B1 (en) 2002-08-13 2012-12-12 N-Dia, Inc. Use of devices and methods for detecting amniotic fluid in vaginal secretions
WO2004021012A2 (en) 2002-08-29 2004-03-11 Diagnostic Technologies Ltd. Method of diagnosis of pregnancy-related complications
WO2004030674A1 (ja) 2002-09-30 2004-04-15 Shionogi & Co., Ltd. プロスタグランジンｄ２、プロスタグランジンｄ２アゴニストおよびプロスタグランジンｄ２アンタゴニストの新規用途
WO2004037206A2 (en) 2002-10-23 2004-05-06 University Of Hawaii Methods for diagnosing and treating pre-term labor
US20040100376A1 (en) 2002-11-26 2004-05-27 Kimberly-Clark Worldwide, Inc. Healthcare monitoring system
AU2003290773A1 (en) 2003-02-05 2004-09-06 Ciphergen Biosystems, Inc. Non-invasive assessment of intra-amniotic environment
US20040266025A1 (en) 2003-02-06 2004-12-30 Durlin Hickok Screening and treatment methods for prevention of preterm delivery
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US8003765B2 (en) 2003-04-09 2011-08-23 Stony Brook Anaesthesiology, University Faculty Practice Corporation Methods, antibodies and kits for detecting cerebrospinal fluid in a sample
US20040203079A1 (en) 2003-04-09 2004-10-14 Research Foundation Of The State University Of New York Methods and kits for detecting cerebrospinal fluid in a sample
US20070003992A1 (en) 2003-04-09 2007-01-04 Pentyala Srinivas N Methods and kits for detecting cerebrospinal fluid in a sample
US8060195B2 (en) 2003-05-02 2011-11-15 The Johns Hopkins University Devices, systems and methods for bioimpedance measurement of cervical tissue and methods for diagnosis and treatment of human cervix
AU2004240705A1 (en) 2003-05-20 2004-12-02 Merck Frosst Canada & Co. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
WO2005007223A2 (en) 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
JP3897117B2 (ja) 2003-09-24 2007-03-22 マルハ株式会社 妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法
WO2005031360A1 (ja) 2003-09-26 2005-04-07 Maruha Corporation 関節リウマチの検出又は鑑別方法及び病期又は機能障害度の判別方法
US20050131287A1 (en) 2003-12-16 2005-06-16 Kimberly-Clark Worldwide, Inc. Detection of premature rupture of the amniotic membrane
DK2299275T3 (en) 2004-07-30 2018-05-07 Adeza Biomedical Corp Classification of oncofetal fetronectin level for pregnancy-related indications
US20080090759A1 (en) 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
US20080254479A1 (en) 2004-08-30 2008-10-16 Cervimark, Llc Methods and Kits For Predicting Risk For Preterm Labor
SG155257A1 (en) 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
EP1839056B1 (en) 2004-12-21 2011-08-03 Yale University Diagnosis of preeclampsia
US20060166242A1 (en) 2005-01-06 2006-07-27 Mount Sinai Hospital Markers of pre-term labor
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
AU2006226891A1 (en) * 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
AU2006268140A1 (en) 2005-07-13 2007-01-18 Expressive Constructs, Inc. Substrates, sensors, and methods for assessing conditions in females
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
WO2007030890A1 (en) 2005-09-15 2007-03-22 Bio Source (Wuhan) Technology Ltd A marker for prolonged rupture of membranes
GT200600457A (es) 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
US8076315B2 (en) 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
US20070111326A1 (en) 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
US20080009552A1 (en) 2006-03-23 2008-01-10 Craig Pennell Markers of pre-term labor
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
JP2009544721A (ja) 2006-07-25 2009-12-17 サノフィ−アベンティス プロスタグランジンｄ２受容体アンタゴニストとしての２−フェニルインドール類
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
DK2083863T3 (da) 2006-10-03 2015-06-22 Genzyme Corp Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
WO2008073491A1 (en) 2006-12-11 2008-06-19 University Of Florida Research Foundation, Inc. System and method for analyzing progress of labor and preterm labor
EP2129660A2 (en) 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CA2673946C (en) 2006-12-26 2014-10-14 Brigham Young University Serum proteomics system and associated methods
JP2010519328A (ja) 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用
US20090058072A1 (en) 2007-08-30 2009-03-05 Shirlee Ann Weber Record sheets with integrated themes
WO2009039476A1 (en) 2007-09-20 2009-03-26 Johns Hopkins University Treatment and prevention of ischemic brain injury
US20110002866A1 (en) 2007-10-31 2011-01-06 Lubit Beverly W Methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent
WO2009059259A2 (en) 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
WO2009061681A2 (en) 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc Antagonists of pgd2 receptors
US20110065139A1 (en) 2007-11-27 2011-03-17 Jacob Mullerad diagnostic device for identifying rupture of membrane during pregnancy
US20130177485A1 (en) 2007-11-27 2013-07-11 Momtec Life Ltd. Of Yazmot Haemek Diagnostic device for identifying rupture of membrane during pregnancy
PT2229358E (pt) 2007-12-14 2011-06-29 Pulmagen Therapeutics Asthma Ltd Indoles e sua utilização terapêutica
WO2009089286A1 (en) 2008-01-07 2009-07-16 Ortho-Clinical Diagnostics, Inc. Determination of sflt-1:angiogenic factor complex
JP2011509985A (ja) 2008-01-18 2011-03-31 プルマジェン セラピューティクス （アズマ） リミテッド Ｃｒｔｈ２受容体に対して活性なインドール
ES2587077T3 (es) 2008-01-25 2016-10-20 Wallac Oy Métodos para determinar el riesgo de anomalías cromosómicas en un feto
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009097579A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health
UA98839C2 (en) 2008-02-01 2012-06-25 Панмира Фармасьютикалз, Ллк. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CN101952244B (zh) 2008-02-01 2014-11-05 潘米拉制药公司 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
WO2009145989A2 (en) 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
PT2288367E (pt) 2008-05-16 2016-02-09 Corthera Inc Relaxina h2 para utilização no tratamento da dilatação cervical prematura
US8501959B2 (en) 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
EP2307362A4 (en) 2008-07-03 2012-05-09 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
FR2934681B1 (fr) 2008-07-29 2011-09-30 Bastien Karkouche Dispositif pour la capture de particules biologiques et utilisation.
CA2735525A1 (en) 2008-08-04 2010-02-11 The Board Of Regents Of The University Of Texas System Multiplexed diagnostic test for preterm labor
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US9180114B2 (en) 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
US20120004233A1 (en) 2009-01-26 2012-01-05 Amira Pharmaceuticals, Inc Tricyclic compounds as antagonists of prostaglandin d2 receptors
US20120046261A1 (en) 2009-02-27 2012-02-23 University Of Utah Research Foundation Compositions and methods for diagnosing and preventing spontaneous preterm birth
GB0905964D0 (en) 2009-04-06 2009-05-20 King S College London Marker
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
US20110090048A1 (en) 2009-09-29 2011-04-21 Li Conan K Data Transmission Device with User Identification Capability
CA2779270A1 (en) 2009-10-29 2011-05-05 The Trustees Of The University Of Pennsylvania Method of predicting risk of preterm birth
WO2011060138A2 (en) 2009-11-12 2011-05-19 Cervilenz Inc. Devices and methods for cervix measurement
CN102667486B (zh) 2009-11-25 2016-03-09 霍洛吉克股份有限公司 羊膜内感染的检测
CA2807050C (en) 2009-12-08 2019-06-18 Ozlem Equils Diagnostic biomarker to identify women at risk for preterm delivery
US8874183B2 (en) 2010-02-18 2014-10-28 The Johns Hopkins University Preterm labor monitor
RU2012143978A (ru) 2010-03-16 2014-04-27 Авентис Фармасьютикалз Инк. Замещенный пиримидин в качестве антагониста рецептора простагландина d2
MX2012010035A (es) 2010-03-16 2012-10-01 Aventis Pharma Inc Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2.
PT2558447E (pt) 2010-03-22 2014-11-25 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9hcarbazol e o seu uso como moduladores do receptor de prostaglandina d2
WO2011119757A2 (en) 2010-03-23 2011-09-29 The Reproductive Research Technologies, Lp Noninvasive measurement of uterine emg propagation and power spectrum frequency to predict true preterm labor and delivery
EP2558868A2 (en) * 2010-04-13 2013-02-20 Pronota NV Biomarkers for hypertensive disorders of pregnancy
AU2011252954B2 (en) * 2010-05-14 2015-04-16 Beth Israel Deaconess Medical Center Extracorporeal devices and methods of treating complications of pregnancy
US20110312928A1 (en) 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US20110318308A1 (en) 2010-06-25 2011-12-29 Winthrop-University Hospital Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis
EP2590944B1 (en) 2010-07-05 2015-09-30 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
AP2013006667A0 (en) 2010-07-12 2013-01-31 Therasyn Sensors Inc A device and methods for in vivo monitoring of an individual
US8765487B2 (en) 2010-09-01 2014-07-01 Clinical Innovations Detection of amniotic fluid in vaginal secretions of pregnant women due to premature rupture of fetal membranes
US8647888B2 (en) 2010-10-01 2014-02-11 Hologic, Inc. Immunoassay test strip for use in a diagnostic system
EP2627781B1 (en) 2010-10-15 2017-02-22 Olink Bioscience AB Dynamic range methods
US20120142559A1 (en) 2010-12-06 2012-06-07 Pronota N.V. Biomarkers and parameters for hypertensive disorders of pregnancy
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
US20120196285A1 (en) 2011-01-31 2012-08-02 Esoterix Genetic Laboratories, Llc Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
ES2650263T3 (es) * 2011-11-09 2018-01-17 F. Hoffmann-La Roche Ag Dinámica de la razón de SFLT-1 o endoglina/PLGF como indicador para preeclampsia inminente y/o síndrome de HELLP
AU2013218753A1 (en) 2012-02-06 2014-09-25 Perkinelmer Biosignal, Inc. Dual-acceptor time-resolved-fret
EP2847354A4 (en) 2012-05-08 2015-12-30 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR ASSESSING A PRE-DECLAMPSY
WO2014001244A1 (en) 2012-06-27 2014-01-03 Roche Diagnostics Gmbh MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
EP2890816B1 (en) 2012-08-30 2019-06-05 Ansh Labs LLC Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia
ES2690782T3 (es) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
EP2965088B1 (en) * 2013-03-04 2018-12-05 IQ Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
CN105917232B (zh) * 2013-12-03 2020-10-16 塞尚公司 用于选择性确定胎盘生长因子2的方法
EP3097422B1 (en) 2014-01-24 2018-07-11 Roche Diagnostics GmbH Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia
WO2015148989A1 (en) 2014-03-27 2015-10-01 Wayne State University Systems and methods to identify and treat subjects at risk for obstetrical complications
MA40325A (fr) 2014-07-30 2016-02-04 Matthew Cooper Procédés et compositions pour diagnostiquer, pronostiquer et confirmer une pré-éclampsie.
US10357469B2 (en) 2015-02-18 2019-07-23 Aston University Diagnostic assay and treatment for preeclampsia
WO2016134324A1 (en) 2015-02-20 2016-08-25 Neoteryx, Llc Method and apparatus for acquiring blood for testing
WO2016149759A1 (en) 2015-03-23 2016-09-29 Adelaide Research & Innovation Pty Ltd Methods and systems for determining risk of a pregnancy complication occurring
EP3502705B1 (en) 2015-09-11 2020-09-09 Universidad de los Andes In vitro method for identifying a pregnancy related disease
NL2016967B1 (en) 2016-06-15 2017-12-21 Iq Products B V Markers and their ratio to determine the risk for early-onset preeclampsia.
US20190353667A1 (en) 2017-02-06 2019-11-21 Astute Medical, Inc. Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
US20190079097A1 (en) 2017-09-13 2019-03-14 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods

Also Published As

Publication number Publication date
US20200264188A1 (en) 2020-08-20
WO2019055661A8 (en) 2020-03-26
AU2018331400A1 (en) 2020-04-02
JP2020533595A (ja) 2020-11-19
WO2019055661A1 (en) 2019-03-21
US20210293824A1 (en) 2021-09-23
EP3682250A1 (en) 2020-07-22
SG11202002065VA (en) 2020-04-29
CN111094988A (zh) 2020-05-01
CA3075688A1 (en) 2019-03-21
US11333672B2 (en) 2022-05-17
US20220268781A1 (en) 2022-08-25
MX2020002788A (es) 2020-09-14
EP3682250A4 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
US11333672B2 (en) Preeclampsia biomarkers and related systems and methods
CN103969455B (zh) 确定产前并发症风险的方法
Easter et al. Urinary tract infection during pregnancy, angiogenic factor profiles, and risk of preeclampsia
Rana et al. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia
AU2010240781B2 (en) Methods for determining maternal health risks
Giguere et al. Screening for pre‐eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers
Yliniemi et al. Combination of PAPPA, fhCGβ, AFP, PIGF, sTNFR1, and maternal characteristics in prediction of early-onset preeclampsia
Than et al. Molecular subclasses of preeclampsia characterized by a longitudinal maternal proteomics study: distinct biomarkers, disease pathways and options for prevention
US20210041469A1 (en) Methods and compositions for diagnosis and prognosis of sepsis
Travaglino et al. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial
JP2022517163A (ja) 臨床的介入のための妊娠の進展および早期流産の評価方法およびその応用
US20250244317A1 (en) Assessment of preeclampsia using assays for free and dissociated placental growth factor
MacKinnon et al. The impact of maternal autoimmune disease on cell-free DNA test characteristics
Oliveira et al. First trimester prediction of HELLP syndrome
Cheng et al. Prognostic value of cardiovascular disease risk factors measured in the first-trimester on the severity of preeclampsia
Degnes et al. Placenta-derived proteins across gestation in healthy pregnancies—a novel approach to assess placental function?
US20190079097A1 (en) Preeclampsia biomarkers and related systems and methods
WO2021113710A1 (en) Assessment of preeclampsia using assays for free and dissociated placental growth factor
US8097424B2 (en) Method for predicting the outcome of a critically ill patient
Svirsky et al. First and second trimester maternal serum inhibin A levels in twins with pre‐eclampsia
Hackelöer et al. Internal and external validation of a machine learning algorithm to detect preeclampsia-related adverse outcomes in high-risk pregnancies
Huang et al. Noninvasive prediction of fetal growth restriction using maternal plasma cell-free RNA: a case-control study
Zamudio et al. From pruritus to cholestasis: Building a statistical model and online application to predict a diagnosis prior to bile acid determination
Gilboa et al. A prediction model for hemolysis, elevated liver enzymes and low platelets syndrome in pre‐eclampsia with severe features
Kim et al. Association of ST2 elevation in the early third trimester with heart failure and pre-eclampsia in the peripartum period

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200406

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210913

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230105

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230314

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230105

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I